Quality Chemical Industries Ltd

Press Releases

Quality Chemical Industries Limited: Post annual general meeting notice

At the Annual General Meeting (AGM) of the company held electronically on Thursday, 17 July 2025, the following resolutions were passed
The pharmaceutical manufacturing plant of Quality Chemical Industries Ltd in Luzira, Kampala. The company manufactures and sells antiretroviral medicines for HIV/AIDS, artemisinin-based combination therapies for malaria and hepatitis B medicines using technology from Cipla Limited.
Companies

Quality Chemical shareholders approve $51m credit facilities

Quality Chemical Industries Limited shareholders voted in favour of the pharmaceutical company's $51m credit facilities provided by Stanbic Bank that will help it increase manufacturing capacity and introduce new products
A group of men on a guided tour, directed by another man, in a pharmaceuticals factory
CompaniesMarketsPress Releases

Quality Chemical Industries Ltd: Notice of annual general meeting

The annual general meeting (AGM) of Quality Chemical Industries Limited (the Company) for the year ending 31 March 2025 will be held electronically on Thursday, 17 July 2025 at 11:00 am EAT
Exterior of Cipla Quality Chemical Industries head offices in Kampala
CompaniesScience & Technology

Quality Chemicals secures $36mn funding from Stanbic Bank to expand production

Quality Chemical Industries Limited, the pharmaceutical company, has secured a $36mn debt facility from Stanbic Bank Uganda for the construction of a second manufacturing facility
Two men signing a host of financing documents
Companies

Cipla Quality Chemical Industries drops Cipla as part of name change

Cipla sold its stake in the drugmaker last November to Africa Capitalworks SSA 3, a Mauritius-based investment vehicle controlled by a South African equity fund
The pharmaceutical manufacturing plant of Quality Chemical Industries Ltd in Luzira, Kampala. The company manufactures and sells antiretroviral medicines for HIV/AIDS, artemisinin-based combination therapies for malaria and hepatitis B medicines using technology from Cipla Limited.